Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (315)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (15)
Medical technologies guidance (7)
Technology appraisal guidance (289)
Apply filters
Showing 251 to 300 of 346
Guidance and quality standards awaiting development
Title
Type
Safeguarding adults in care homes
Quality standard
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237
Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Technology appraisal guidance
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over TS ID 11846
Technology appraisal guidance
Secondary care management of malignant hypertension
Quality standard
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Technology appraisal guidance
Selpercatinib for treating advanced thyroid cancer with RET alterations (MA review of TA742) [ID6288]
Technology appraisal guidance
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options TS ID 11850
Technology appraisal guidance
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441
Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis TS ID 11945
Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)
Technology appraisal guidance
Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]
Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995
Technology appraisal guidance
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827
Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionals
Quality standard
Single-step scaffold insertion for repairing symptomatic chondral knee defects
Interventional procedures guidance
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147
Technology appraisal guidance
Sleep disordered breathing
Quality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needs
Quality standard
Sodium zirconium cyclosilicate for the first line treatment of hyperkalaemia [ID6439]
Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]
Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Technology appraisal guidance
Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions
Medical technologies guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Technology appraisal guidance
STS101 for treating acute migraine TS ID 11782
Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409
Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977
Technology appraisal guidance
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008
Technology appraisal guidance
Supporting independent living and preventing isolation in adults of working age with social care needs
Quality standard
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413
Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation TSID 12009
Technology appraisal guidance
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]
Technology appraisal guidance
Targeted Muscle Reinnervation for refractory pain after limb amputation
Interventional procedures guidance
Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]
Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]
Technology appraisal guidance
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]
Technology appraisal guidance
Teprotumumab for treating thyroid eye disease ID 6432
Technology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918
Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound
Medical technologies guidance
Thyroid disease
Quality standard
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]
Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]
Technology appraisal guidance
Tinnitus
Quality standard
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer TS ID 11951
Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation TS ID 11841
Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]
Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome TS ID 11794
Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID 5077]
Technology appraisal guidance
Previous page
1
…
4
5
Current page
6
7
Page
6
of
7
Next page
Results per page
10
25
50
All
Back to top